Press Releases
Information updates and press releases issued by Deep Genomics

BioMarin and Deep Genomics to Collaborate on Advancing Programs Identified Using Artificial Intelligence

November 17, 2020

 Deep Genomics

SAN RAFAEL and TORONTO, Nov. 17, 2020 — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Deep Genomics today announced that the companies have entered into a preclinical collaboration that will use Deep Genomics’ artificial intelligence drug discovery platform (The AI Workbench) to identify oligonucleotide drug candidates in ...

Amanda Kay Appointed Chief Business Officer of Deep Genomics, Tasked with Overseeing Expansion of Partnership Strategy

November 5, 2020

Company also announces appointment of Tom Hughes, Boston-based biotech builder and CEO of  Navitor Pharmaceuticals, to board of directors.
Company now advancing multiple programs in neurodevelopmental, neurodegenerative and  metabolic disorders.

TORONTO – November 5, 2020. Deep Genomics, the leading artificial intelligence (AI) therapeutics  company, announced today ...

Deep Genomics Appoints Veteran Ferdinand Massari as Chief Medical Officer

September 29, 2020


TORONTO September 29, 2020. Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today that Ferdinand Massari, M.D., has been appointed Chief Medical Officer. Dr. Massari is based in Boston and will oversee clinical development and contribute to expanding the company’s AI ...

DEEP GENOMICS RAISES $40 MILLION IN SERIES B FINANCING

January 7, 2020


  •   Led by Future Ventures, includes top healthcare and technology funds Amplitude Ventures, Khosla Ventures, Magnetic Ventures and True Ventures

  •   Proceeds will support creating new technology for artificial intelligence-accelerated therapeutic development and advancing Wilson disease program into the clinic 

TORONTO – January 7, 2020. Deep Genomics, the ...

DEEP GENOMICS NOMINATES INDUSTRY'S FIRST AI - DISCOVERED THERAPEUTIC CANDIDATE

September 25, 2019

Artificial Intelligence enables target and drug candidate to be identified in less than 18 months. Initial target of Wilson disease represents significant clinical need, new era of drug discovery.

Toronto, Ontario ​– September 25, 2019. Deep Genomics, the leading AI therapeutics company, announced today that its proprietary artificial intelligence-based drug discovery platform has identified a novel treatment target and corresponding drug candidate for Wilson disease, a rare, serious, and potentially life-threatening genetic disorder.

“This is ...

DEEP GENOMICS PLANS FOR CLINICAL INNOVATION, APPOINTS PETER BARTON HUTT AS STRATEGIC ADVISOR

June 25, 2019

 Deep Genomics is proud to announce that Peter Barton Hutt, Senior Counsel at Covington & Burling and former Chief Counsel of the U.S. Food and Drug Administration, has joined the company as a Strategic Advisor. 

Toronto, Ontario – June 26, 2019 at 9:00 AM EDT. Deep Genomics, the leading AI therapeutics company, announced today that Peter Barton Hutt, Senior Counsel at Covington & Burling and former Chief Counsel of the U.S. Food and Drug Administration, has joined the company ...

DEEP GENOMICS APPOINTS JAMES DOWLING AS CHIEF MEDICAL OFFICER

June 24, 2019

James Dowling, M.D., Ph.D. is joining the leadership team at Deep Genomics as Chief Medical Officer. Jim's understanding of patient needs combined with expertise on rare disease biology is crucial to guide the design of AI systems to accelerate clinical development. 

Toronto, Ontario – June 24, 2019 at 9:00 AM EDT. Deep Genomics, the leading AI therapeutics company, announced today that James Dowling, M.D., Ph.D., is joining the team as Chief Medical Officer, effective today.

“Deep Genomics has identified therapeutic opportunities addressing hundreds of ...

DEEP GENOMICS EXPANDS LABORATORY, APPOINTS JOHAN FRANSSON AS HEAD OF PRECLINICAL RESEARCH

June 18, 2019

To support preclinical research and address the growing number of programs in our pipeline, Deep Genomics has expanded our experimental facility and appointed Johan Fransson.

TORONTO, Ontario, Canada – June 18, 2019. Deep Genomics, the leading AI therapeutics company, announced today that the output of its discovery pipeline has quadrupled in the past year and that it has appointed Johan Fransson, Ph.D. as Head of Preclinical Research, effective immediately.

“We ...